Discovery and developmentof GRK2-biased beta 2-adrenergic receptor agonists for the treatment of metabolic disorders
Presenter: Dr Benjamin Pelcman, Atrogi AB Atrogi AB is biotech company pioneering first-in-class treatments to revolutionize metabolic health. The talk will describe how targeting a novel GRK-biased b2-adrenergic receptor signaling pathway allows for the successful design of compounds useful in the treatment of disorders like type 2 diabetes (T2D), obesity and muscular wasting. The approach […]